Rchr
J-GLOBAL ID：202301012446496073
Update date: May. 07, 2024
Yasuyuki Mizutani
ミズタニ ヤスユキ | Yasuyuki Mizutani
Affiliation and department：
Job title：
Assistant professor of hospital
Research field (2)：
Gastroenterology
, Tumor biology
Research keywords (4)：
Meflin
, Cancer restraining CAF
, 膵癌
, 癌関連線維芽細胞
Research theme for competitive and other funds (6)：
Papers (27)：
-
Shuji Ikegami, Keiko Maeda, Takeshi Urano, Jingxi Mu, Masanao Nakamura, Takeshi Yamamura, Tsunaki Sawada, Eri Ishikawa, Kenta Yamamoto, Hisanori Muto, et al. Monoclonal Antibody Against Mature Interleukin-18 Ameliorates Colitis in Mice and Improves Epithelial Barrier Function. Inflammatory Bowel Diseases. 2023
-
Ryota Ando, Yukihiro Shiraki, Yuki Miyai, Hiroki Shimizu, Kazuhiro Furuhashi, Shun Minatoguchi, Katsuhiro Kato, Akira Kato, Tadashi Iida, Yasuyuki Mizutani, et al. Meflin is a marker of pancreatic stellate cells involved in fibrosis and epithelial regeneration in the pancreas. The Journal of pathology. 2023
-
Ryota Ando, Akihiro Sakai, Tadashi Iida, Kunio Kataoka, Yasuyuki Mizutani, Atsushi Enomoto. Good and Bad Stroma in Pancreatic Cancer: Relevance of Functional States of Cancer-Associated Fibroblasts. Cancers. 2022. 14. 14
-
Tadashi Iida, Yasuyuki Mizutani, Nobutoshi Esaki, Suzanne M Ponik, Brian M Burkel, Liang Weng, Keiko Kuwata, Atsushi Masamune, Seiichiro Ishihara, Hisashi Haga, et al. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics. Oncogene. 2022. 41. 23. 3302-3302
-
Iida T, Mizutani Y, Esaki N, Ponik SM, Burkel BM, Weng L, Kuwata K, Masamune A, Ishihara S, Haga H, et al. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics. Oncogene. 2022. 41. 19. 2764-2777
ｍore...
MISC (9)：
-
飯田 忠, 水谷 泰之, 石川 卓哉, 大野 栄三郎, 川嶋 啓揮, 榎本 篤, 藤城 光弘. 【膵癌研究最前線】癌関連線維芽細胞をターゲットにした新たな治療法. 消化器・肝臓内科. 2021. 10. 3. 382-386
-
飯田 忠, 水谷 泰之, 榎本 篤. がん関連線維芽細胞の多様性・機能多面性 線維芽細胞は「疾患抑制システム」の構成因子か. 臨床免疫・アレルギー科. 2021. 76. 2. 196-201
-
水谷 泰之, 飯田 忠, 石川 卓哉, 大野 栄三郎, 川嶋 啓揮, 藤城 光弘, 榎本 篤. 【膵癌、膵炎の病態解明と新規治療開発にむけた研究の最前線】癌抑制性癌関連線維芽細胞の同定とその臨床応用について. 胆と膵. 2021. 42. 8. 711-715
-
水谷 泰之, 高橋 雅英, 榎本 篤. Meflin陽性癌関連線維芽細胞は膵癌において発癌を抑制する(Meflin defines cancer-associated fibroblasts that suppress pancreatic cancer progression). 日本病理学会会誌. 2020. 109. 1. 323-323
-
水谷 泰之, 榎本 篤, 高橋 雅英. 腫瘍抑制性癌関連線維芽細胞の同定(Meflin defines cancer-associated fibroblasts that suppress pancreatic cancer progression). 日本癌学会総会記事. 2019. 78回. E-3001
ｍore...
Patents (2)：
-
レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
-
未分化間葉系幹細胞マーカー及びその用途
Books (3)：
-
【膵臓の発生・生理・解剖から膵炎・膵癌の病態解明に至る最新の知見】がん抑制性線維芽細胞の本態の理解とその治療応用について
医学図書出版 2022
-
胆と膵:膵癌,膵炎の病態解明と新規治療開発にむけた研究の最前線
医学図書出版 2021 ISBN:9784865174328
-
膵癌・胆道癌 基礎と臨床の最新研究動向 2015年 03 月号
日本臨牀社 2015
Lectures and oral presentations (3)：
-
SAFETY AND EFFICACY OF AM80 IN PATIENTS WITH ADVANCED PANCREATIC CANCER: A STUDY PROTOCOL FOR AN OPEN-LABEL PHASE I/II INVESTIGATOR-INITIATED CLINICAL TRIAL BASED ON A DRUG REPOSITIONING APPROACH THAT REPROGRAMS THE TUMOUR STROMA
(2022)
-
Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis
(UEG 2019)
-
IDENTIFICATION OF THE CANCER-SUPPRESSING CANCER-ASSOCIATED FIBROBLASTS
Work history (2)：
- 2018/04 - 現在 Nagoya University Nagoya University Hospital Gastroenterology Assistant professor of hospital
- 2021/04 - Nagoya University Assistant professor of hospital
Awards (2)：
- 2019/10 - United European Gastroenterology Week 2019 Rising Stars in gastroenterology and hepatology from Europe and Japan
- 2014/07 - 日本膵臓学会 日本膵臓学会学会奨励賞
Return to Previous Page
